KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Income towards Common Stockholders: 2020-2025

Historic Net Income towards Common Stockholders for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$162.3 million.

  • Recursion Pharmaceuticals' Net Income towards Common Stockholders fell 69.29% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 89.42%. This contributed to the annual value of -$463.7 million for FY2024, which is 41.33% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at -$162.3 million for Q3 2025, which was up 5.61% from -$171.9 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at -$30.5 million for Q1 2021, and its period low was -$202.5 million during Q1 2025.
  • In the last 3 years, Recursion Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$95.8 million in 2024 and averaged -$120.8 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first slumped by 153.94% in 2021, then rose by 6.12% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$65.0 million in 2021, then grew by 6.12% to -$61.0 million in 2022, then tumbled by 52.50% to -$93.0 million in 2023, then crashed by 92.38% to -$178.9 million in 2024, then crashed by 69.29% to -$162.3 million in 2025.
  • Its Net Income towards Common Stockholders was -$162.3 million in Q3 2025, compared to -$171.9 million in Q2 2025 and -$202.5 million in Q1 2025.